Cancer in systemic sclerosis

Ami Shah, Masataka Kuwana

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

It has long been recognized that patients with systemic sclerosis (scleroderma) have a higher risk of cancer compared to individuals in the general population. This increased risk could be secondary to damage from the disease process itself, a consequence of the immunosuppressive and cytotoxic therapies used to treat scleroderma, common environmental exposures, or from a shared genetic predisposition to develop both cancer and autoimmunity. Alternatively, it has been hypothesized that cancer therapies, including various chemotherapeutic agents and radiation therapy, may trigger the development of vascular and fibrotic complications characteristic of scleroderma. Recent data demonstrate that a subset of patients have paraneoplastic scleroderma due to the development of antitumor immune responses that may become cross-reactive and result in autoimmunity. In this chapter, we explore these potential links between cancer and scleroderma, discuss a paraneoplastic model of scleroderma pathogenesis, and suggest implications for cancer screening and therapeutics in this patient population.

Original languageEnglish (US)
Title of host publicationScleroderma: From Pathogenesis to Comprehensive Management
PublisherSpringer International Publishing
Pages525-532
Number of pages8
ISBN (Electronic)9783319314075
ISBN (Print)9783319314051
DOIs
StatePublished - Jan 1 2016

Fingerprint

Systemic Scleroderma
Autoimmunity
Neoplasms
Environmental Exposure
Genetic Predisposition to Disease
Immunosuppressive Agents
Early Detection of Cancer
Population
Blood Vessels
Radiotherapy
Therapeutics

Keywords

  • Cancer
  • Malignancy screening
  • Paraneoplastic
  • Risk factors
  • RNA polymerase III autoantibodies
  • Systemic sclerosis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Shah, A., & Kuwana, M. (2016). Cancer in systemic sclerosis. In Scleroderma: From Pathogenesis to Comprehensive Management (pp. 525-532). Springer International Publishing. https://doi.org/10.1007/978-3-319-31407-5_37

Cancer in systemic sclerosis. / Shah, Ami; Kuwana, Masataka.

Scleroderma: From Pathogenesis to Comprehensive Management. Springer International Publishing, 2016. p. 525-532.

Research output: Chapter in Book/Report/Conference proceedingChapter

Shah, A & Kuwana, M 2016, Cancer in systemic sclerosis. in Scleroderma: From Pathogenesis to Comprehensive Management. Springer International Publishing, pp. 525-532. https://doi.org/10.1007/978-3-319-31407-5_37
Shah A, Kuwana M. Cancer in systemic sclerosis. In Scleroderma: From Pathogenesis to Comprehensive Management. Springer International Publishing. 2016. p. 525-532 https://doi.org/10.1007/978-3-319-31407-5_37
Shah, Ami ; Kuwana, Masataka. / Cancer in systemic sclerosis. Scleroderma: From Pathogenesis to Comprehensive Management. Springer International Publishing, 2016. pp. 525-532
@inbook{ce9c1966039243e1b58edf13acfc82b4,
title = "Cancer in systemic sclerosis",
abstract = "It has long been recognized that patients with systemic sclerosis (scleroderma) have a higher risk of cancer compared to individuals in the general population. This increased risk could be secondary to damage from the disease process itself, a consequence of the immunosuppressive and cytotoxic therapies used to treat scleroderma, common environmental exposures, or from a shared genetic predisposition to develop both cancer and autoimmunity. Alternatively, it has been hypothesized that cancer therapies, including various chemotherapeutic agents and radiation therapy, may trigger the development of vascular and fibrotic complications characteristic of scleroderma. Recent data demonstrate that a subset of patients have paraneoplastic scleroderma due to the development of antitumor immune responses that may become cross-reactive and result in autoimmunity. In this chapter, we explore these potential links between cancer and scleroderma, discuss a paraneoplastic model of scleroderma pathogenesis, and suggest implications for cancer screening and therapeutics in this patient population.",
keywords = "Cancer, Malignancy screening, Paraneoplastic, Risk factors, RNA polymerase III autoantibodies, Systemic sclerosis",
author = "Ami Shah and Masataka Kuwana",
year = "2016",
month = "1",
day = "1",
doi = "10.1007/978-3-319-31407-5_37",
language = "English (US)",
isbn = "9783319314051",
pages = "525--532",
booktitle = "Scleroderma: From Pathogenesis to Comprehensive Management",
publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Cancer in systemic sclerosis

AU - Shah, Ami

AU - Kuwana, Masataka

PY - 2016/1/1

Y1 - 2016/1/1

N2 - It has long been recognized that patients with systemic sclerosis (scleroderma) have a higher risk of cancer compared to individuals in the general population. This increased risk could be secondary to damage from the disease process itself, a consequence of the immunosuppressive and cytotoxic therapies used to treat scleroderma, common environmental exposures, or from a shared genetic predisposition to develop both cancer and autoimmunity. Alternatively, it has been hypothesized that cancer therapies, including various chemotherapeutic agents and radiation therapy, may trigger the development of vascular and fibrotic complications characteristic of scleroderma. Recent data demonstrate that a subset of patients have paraneoplastic scleroderma due to the development of antitumor immune responses that may become cross-reactive and result in autoimmunity. In this chapter, we explore these potential links between cancer and scleroderma, discuss a paraneoplastic model of scleroderma pathogenesis, and suggest implications for cancer screening and therapeutics in this patient population.

AB - It has long been recognized that patients with systemic sclerosis (scleroderma) have a higher risk of cancer compared to individuals in the general population. This increased risk could be secondary to damage from the disease process itself, a consequence of the immunosuppressive and cytotoxic therapies used to treat scleroderma, common environmental exposures, or from a shared genetic predisposition to develop both cancer and autoimmunity. Alternatively, it has been hypothesized that cancer therapies, including various chemotherapeutic agents and radiation therapy, may trigger the development of vascular and fibrotic complications characteristic of scleroderma. Recent data demonstrate that a subset of patients have paraneoplastic scleroderma due to the development of antitumor immune responses that may become cross-reactive and result in autoimmunity. In this chapter, we explore these potential links between cancer and scleroderma, discuss a paraneoplastic model of scleroderma pathogenesis, and suggest implications for cancer screening and therapeutics in this patient population.

KW - Cancer

KW - Malignancy screening

KW - Paraneoplastic

KW - Risk factors

KW - RNA polymerase III autoantibodies

KW - Systemic sclerosis

UR - http://www.scopus.com/inward/record.url?scp=85018881993&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018881993&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-31407-5_37

DO - 10.1007/978-3-319-31407-5_37

M3 - Chapter

AN - SCOPUS:85018881993

SN - 9783319314051

SP - 525

EP - 532

BT - Scleroderma: From Pathogenesis to Comprehensive Management

PB - Springer International Publishing

ER -